Giroctocogene fitelparvovec, a novel gene therapy, demonstrated superiority to routine therapy in treating hemophilia A. Giroctocogene fitelparvovec resulted in a ...
Hemophilia B patients given Beqvez had a decreased incidence of total bleeding Beqvez reduced the use of routine factor IX ...
1. The first dose of adenoviral-based Oxford-AstraZeneca and Janssen vaccines was associated with acute myocardial infarction and pulmonary embolism. 2. ...
1. Heterologous AstraZeneca followed by Pfizer vaccination was noninferior to homologous, two-dose AstraZeneca vaccination with a geometric mean ratio of ...
Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group ...
1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 ...
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their ...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. ...
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one ...
